Tag: sessions

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),² and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association^®, held in New Orleans, Louisiana from June 5-8, 2026.